Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

BACKGROUND: In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo. OBJECTIVE: To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup analyses. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Cree, Bruce AC, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary R, Marignier, Romain, Green, Ari J, Aktas, Orhan, Hartung, Hans-Peter, Williams, Ian M, Drappa, Jorn, She, Dewei, Cimbora, Daniel, Rees, William, Ratchford, John N, Katz, Eliezer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564264/
https://www.ncbi.nlm.nih.gov/pubmed/33538237
http://dx.doi.org/10.1177/1352458521988926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564264/
https://www.ncbi.nlm.nih.gov/pubmed/33538237
http://dx.doi.org/10.1177/1352458521988926

Ejemplares similares